88 related articles for article (PubMed ID: 16904427)
1. Role of vascular endothelial growth factor in prostate cancer.
Delongchamps NB; Peyromaure M; Dinh-Xuan AT
Urology; 2006 Aug; 68(2):244-8. PubMed ID: 16904427
[No Abstract] [Full Text] [Related]
2. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
3. Medicinal mushroom cuts off prostate cancer cells' blood supply.
Johnston N
Drug Discov Today; 2005 Dec; 10(23-24):1584. PubMed ID: 16376814
[No Abstract] [Full Text] [Related]
4. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
[TBL] [Abstract][Full Text] [Related]
5. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
Tesan T; Gustavsson H; Welén K; Damber JE
BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
[TBL] [Abstract][Full Text] [Related]
9. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
10. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ; Ortiz J; Cooney MM; Remick SC
J Clin Oncol; 2007 Jul; 25(21):2993-5. PubMed ID: 17634476
[No Abstract] [Full Text] [Related]
11. [Diffusion weighted MRI helps evaluate angiogenesis and vascular endothelial growth factor expression in prostate cancer].
Liu JG; Wang B; Wang XZ; Niu QL; Zhang Q
Zhonghua Nan Ke Xue; 2009 May; 15(5):403-8. PubMed ID: 19514550
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
Jain S; Chakraborty G; Raja R; Kale S; Kundu GC
Cancer Res; 2008 Oct; 68(19):7750-9. PubMed ID: 18829529
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
14. Modulation of 11beta-hydroxysteroid dehydrogenase expression by bombesin: a possible mechanism for glucocorticoid resistance in androgen independent prostate cancer.
Lee JG; Ge R; Hardy DO; Leong K; Nanus DM; Hardy MP; Shen R
Horm Metab Res; 2008 Nov; 40(11):772-8. PubMed ID: 18726827
[TBL] [Abstract][Full Text] [Related]
15. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.
Caine GJ; Ryan P; Lip GY; Blann AD
Cancer Lett; 2007 Jun; 251(2):296-301. PubMed ID: 17240049
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis.
Ren J; Huan Y; Wang H; Chang YJ; Zhao HT; Ge YL; Liu Y; Yang Y
Clin Radiol; 2008 Feb; 63(2):153-9. PubMed ID: 18194690
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Zeng Y; Opeskin K; Goad J; Williams ED
Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
[TBL] [Abstract][Full Text] [Related]
18. Promoting angiogenesis to a fault.
Hicklin DJ
Nat Biotechnol; 2007 Mar; 25(3):300-2. PubMed ID: 17344881
[No Abstract] [Full Text] [Related]
19. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
